{"data":{"type":"company_profile_ai","id":141810,"entity_id":"wefunder:company:141810","attributes":{"canonical_url":"https://wefunder.com/pirouette","retrieval_urls":{"canonical":"https://wefunder.com/pirouette","json":"https://wefunder.com/pirouette.json","markdown":"https://wefunder.com/pirouette.md","ai_json":"https://wefunder.com/pirouette.ai.json","ai_text":"https://wefunder.com/pirouette.ai.txt","changelog_json":"https://wefunder.com/pirouette.changelog.json","schema":"https://wefunder.com/.well-known/ai-profile-schema.json"},"updated_at":"2026-06-03T16:03:34Z","generated_at":"2026-06-03T23:38:45Z","profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"company":{"id":141810,"entity_id":"wefunder:company:141810","slug":"pirouette","name":"Pirouette Pharma (YC S21)","tagline":"Reengineering life-saving injections; #1 most raised campaign in Wefunder history","location":"Portsmouth, NH","website":"https://pirouettepharma.com/","total_amount_raised":12755159,"total_investors":4910,"is_funded":true,"is_active":true},"key_claims":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 12755159","citation":"https://wefunder.com/pirouette#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-03T16:03:34Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-04T16:03:34Z"},{"claim_id":"claim-total-investors","text":"Total investors: 4910","citation":"https://wefunder.com/pirouette#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-03T16:03:34Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-04T16:03:34Z"}],"verified_facts":[{"claim_id":"claim-total-raised","text":"Total raised on Wefunder: 12755159","citation":"https://wefunder.com/pirouette#claim-total-raised","provenance":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-03T16:03:34Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-04T16:03:34Z"},{"claim_id":"claim-total-investors","text":"Total investors: 4910","citation":"https://wefunder.com/pirouette#claim-total-investors","provenance":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-03T16:03:34Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-04T16:03:34Z"}],"company_claims":{"tagline":"Reengineering life-saving injections; #1 most raised campaign in Wefunder history","story":"Earlier this year, this community raised $7.8 million on Wefunder—the most funded campaign in the platform's history—proving how powerful mission‑driven capital can be when aligned with patient impact. Demand exceeded our allocation, so before our next institutional raise, we're reopening a final window for our community to join the next phase of growth.​The Problem: Injections at Home Are BrokenPatients are stuck with outdated devices where visible needles trigger fear, leading to delayed treatment, errors, and poor adherence—driving them back to clinics and increasing costs. We're changing that. Instead of forcing life to adapt to treatment, our hidden-needle design makes care simple, consistent, and fear-free.​Our Solution: OnePush™OnePush is our patented, disc‑shaped push-button auto‑injector designed for real life—drug‑agnostic, partner‑ready, and engineered to turn chronic therapies into a preferred patient experience at scale.​Hidden‑Needle Comfort: Fully automatic—the needle is designed to stay invisible before, during, and after injection, with smooth insertion engineered to reduce sensation and prevent anxiety.​Battlefield‑Grade Engineering: ISO‑aligned, rugged performance aiming for first‑try success in any environment.​Made in America: Scaling automated U.S. manufacturing for speed, quality, and confidence.​The OpportunitySterile injectable delivery is a trillion-dollar global market by 2029. We're positioning OnePush to capture a meaningful share of the $150‑billion GLP‑1 class—including Wegovy®, Ozempic®, and Zepbound®—by pairing blockbuster therapies with device‑driven adherence and potential retail access for millions.​Since Our Last Wefunder Raise, We've ExecutedValidated U.S. manufacturing, increased our global patent count to 23 granted, completed a successful FDA Type C meeting supporting over‑the‑counter potential, and built a pipeline with $800M+ in near‑term licensing opportunities.​Join UsWe invite you to be part of this next chapter: scaling automated manufacturing, advancing FDA submissions, and commercializing OnePush to put best‑in‑class self‑injection in the hands of millions.Here's to transforming healthcare, together.ConorFounder \u0026amp; CEO, PirouetteMost patients are still self‑injecting with decades‑old pens and prefilled syringes that force them to stare at exposed needles, manage multiple preparation steps, and hope they did everything correctly. These experiences fuel anxiety, fear, and second‑guessing, and too often lead to delayed doses, avoidable errors, and people quietly abandoning treatment at home.Needle fear affects over 50% of patients, causing hesitation and poor adherence.Most devices rely on bulky, plastic-wrapped syringes or outdated auto-injectors that expose the needle, require high force, and weren’t designed with patients in mind.Even when home use is possible, most injectable medications are still delivered in clinics or pharmacies. Even a routine post-chemotherapy injection can mean driving back to the hospital and home again all for a single shot.Our patented OnePush™ auto-injector platform simplifies the delivery of all injectable drugs.With the global injectable medicine market rapidly expanding to nearly $1T, Pirouette’s OnePush auto-injector is designed to improve brand differentiation and adoption by delivering a more patient‑preferred injection experience. Pirouette’s hidden‑needle comfort for home use reduces needle visibility and sensation, helping patients start and stay on essential medications. This leads to both preference and brand loyalty while supporting better long‑term outcomes and quality of life.With a fully automatic, hidden needle engineered to reduce needle sensation and ease self‑injection anxiety, it strengthens comfort and consistency across a wide range of therapies – from weekly GLP-1s for diabetes and obesity to oncology therapies and HIV medications, as well as hormone injections for IVF.Pirouette is advancing on every front with global patent protection, U.S. manufacturing already online, fully automated high‑through put capacity in development for build‑out in 2026, and a defined regulatory path that keeps us on track for a first FDA approval in under two years and a second within three. We’re primed to scale and commercialize across priority programs.We own the IP and have Freedom to Operate ClearancePirouette’s competitive advantage is backed by one of the strongest intellectual property positions in the industry. We engaged one of the world’s top intellectual property law firms to conduct a rigorous global patent landscape search. Their conclusion: no other company’s patents stand in our way.This gives us an unprecedented legal “green light” to manufacture and sell our flagship OnePush™ auto-injector worldwide, without fear of infringing on others or being blocked by competitor lawsuits. This level of clarity is incredibly rare in medtech, and it’s a major moat for Pirouette.We also fully own the manufacturing IP: every step of the device assembly process, inspection protocol, and production tooling is protected and proprietary. This means we can build, scale, and ship on our own terms—without relying on third parties or risking production disruption. No one else can manufacture OnePush without us.First, we partner with big pharmaceutical companies. They bring us their blockbuster medicines—drugs that are already proven and approved—and we package them into OnePush. These partnerships generate upfront payments, development milestones, and ongoing royalties every time a dose is sold, creating a steady revenue stream without Pirouette having to sell the drugs ourselves.Second, we bring our own medicines to market. We take proven, well-established injectable drugs that are losing or have lost patent protection—including blockbuster GLP-1 therapies like semaglutide (the active ingredient in Wegovy® and Ozempic®) and dulaglutide (Trulicity®)—and pair them with OnePush using streamlined FDA pathways called 505(b)(2) and 351(k).These pathways let us rely on existing safety and effectiveness data for the drug itself, so we only need to run studies proving our device delivers the dose correctly and that patients can use it easily at home. When we launch these products under our own brand, Pirouette captures the full revenue and profit margin—not just royalties.​Together, these two models give us multiple shots on goal: steady partnership income and the potential for high-margin product sales as we scale.Disclaimer: Certain information set forth on this page contains \"forward-looking information\", including \"future-oriented financial information\" and \"financial outlook\", under applicable securities laws. These are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance. All investments involve risk, including the potential loss of capital. Pirouette’s products presented are not approved by regulatory authorities in any markets and the statements in this presentation represent design intent and are not product claims.","quick_facts":["#1 Wefunder raise in history ($7.8M; 4000+ investors) + backed by top life sciences VCs","$800M+ in licensing deal potential with 4 medications targeting FDA approval in 2027, 2028, and 2029","Big pharma + an aerospace leader are in advanced talks to use OnePush across multiple medicines","23 granted patents globally with more pending; clear path to commercialize worldwide by 2027","100% of oncologists would prescribe OnePush over current auto-injectors in blinded research study","OnePush targets a $1T dollar injectable market as self‑care shifts to simpler at‑home devices","Type C Meeting with FDA gave a defined path for an OTC approval—a validation of its ease of use!","$600M+ projected in annual sales by year 5 (not guaranteed)"]},"computed_metrics":{"total_amount_raised":12755159,"total_investors":4910,"team_size":10,"featured_investor_count":10,"faq_count":5,"recent_post_count":0},"quick_facts":[{"claim_id":"claim-fact-1","value":"#1 Wefunder raise in history ($7.8M; 4000+ investors) + backed by top life sciences VCs","citation":"https://wefunder.com/pirouette#claim-fact-1","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-2","value":"$800M+ in licensing deal potential with 4 medications targeting FDA approval in 2027, 2028, and 2029","citation":"https://wefunder.com/pirouette#claim-fact-2","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-3","value":"Big pharma + an aerospace leader are in advanced talks to use OnePush across multiple medicines","citation":"https://wefunder.com/pirouette#claim-fact-3","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-4","value":"23 granted patents globally with more pending; clear path to commercialize worldwide by 2027","citation":"https://wefunder.com/pirouette#claim-fact-4","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-5","value":"100% of oncologists would prescribe OnePush over current auto-injectors in blinded research study","citation":"https://wefunder.com/pirouette#claim-fact-5","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-6","value":"OnePush targets a $1T dollar injectable market as self‑care shifts to simpler at‑home devices","citation":"https://wefunder.com/pirouette#claim-fact-6","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-7","value":"Type C Meeting with FDA gave a defined path for an OTC approval—a validation of its ease of use!","citation":"https://wefunder.com/pirouette#claim-fact-7","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"},{"claim_id":"claim-fact-8","value":"$600M+ projected in annual sales by year 5 (not guaranteed)","citation":"https://wefunder.com/pirouette#claim-fact-8","observed_at":"2026-06-03T16:03:34Z","expires_at":"2026-06-10T16:03:34Z"}],"latest_fundraise":{"id":149523,"entity_id":"wefunder:fundraise:149523","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null},"investor_memos":[{"investor_name":"Safar Partners","investor_entity_id":"wefunder:notable_investor:3937","memo_url":"https://uploads.wefunder.com/uploads/remote_files/831622-SbCdhn0WjfMdhoJ8OA0m3wtA/Pirouette_Safar_Partners_Investment_Memo_20240515.pdf","claim_id":"claim-investor-memo-1","citation":"https://wefunder.com/pirouette#claim-investor-memo-1","paid_for_by_company":false},{"investor_name":"Kingscrowd Capital","investor_entity_id":"wefunder:user:4138054","memo_url":"https://kingscrowd.com/pirouette-medical-on-wefunder-2024/","claim_id":"claim-investor-memo-2","citation":"https://wefunder.com/pirouette#claim-investor-memo-2","paid_for_by_company":false}],"team":[{"id":3847364,"entity_id":"wefunder:company_role:3847364","name":"Conor R. Cullinane, Ph.D.","title":"President \u0026 CEO","role":"founder","profile_url":"https://wefunder.com/conor.cullinane"},{"id":4023860,"entity_id":"wefunder:company_role:4023860","name":"Elijah Kapas","title":"CTO","role":"founder"},{"id":4023858,"entity_id":"wefunder:company_role:4023858","name":"Matthew Kane","title":"COO","role":"founder"},{"id":6559992,"entity_id":"wefunder:company_role:6559992","name":"Kevin Statz","title":"Chief Commercial Officer","role":"employee"},{"id":6559993,"entity_id":"wefunder:company_role:6559993","name":"Erin Beauregard","title":"Chief of Staff","role":"employee"},{"id":6559994,"entity_id":"wefunder:company_role:6559994","name":"Phil Littlefield","title":"VP of Supply Chain","role":"employee"},{"id":6559995,"entity_id":"wefunder:company_role:6559995","name":"Emily Deane","title":"VP of Quality","role":"employee"},{"id":6559996,"entity_id":"wefunder:company_role:6559996","name":"Thomas J. Hook","title":"Lead Investor","role":"employee"},{"id":6559997,"entity_id":"wefunder:company_role:6559997","name":"Joe Nemmers","title":"Director \u0026 Board Member","role":"employee"},{"id":4159544,"entity_id":"wefunder:company_role:4159544","name":"Surbhi Sarna","title":"Investor \u0026 Advisor","role":"employee"}],"featured_investors":[{"id":6493,"entity_id":"wefunder:company_investor_profile:6493","name":"Safar Partners","bio":"Safar Partners nurtures innovations in sustainable energy, clean water, food management, and healthcare to tackle today’s biggest challenges, including climate change and global health.","profile_url":"https://wefunder.com/safar.partners","endorsement_quote":"An investment in Pirouette is not just promising; it's a unique opportunity seldom seen in the medical industry, where the public can directly invest in an emerging medical company that will save lives and enable affordable healthcare. Pirouette is poised to revolutionize the $600 billion injectable drug market and transform how life-saving injections are administered and accessed.","memo_url":"https://uploads.wefunder.com/uploads/remote_files/831622-SbCdhn0WjfMdhoJ8OA0m3wtA/Pirouette_Safar_Partners_Investment_Memo_20240515.pdf"},{"id":8827,"entity_id":"wefunder:company_investor_profile:8827","name":"Kingscrowd Capital","bio":"KingsCrowd Capital is the first 'index'-like fund product that utilizes a data-driven investment approach.","profile_url":"https://wefunder.com/kingscrowd.capital","endorsement_quote":"With a dedicated founding team and support from notable accelerators and venture capital firms, including Y Combinator, Safar Partners, Liquid 2 Ventures, Magic Fund, and Asymmetry Ventures, Pirouette Medical is well-positioned to advance its product offering. The company’s product addresses a significant market need for more affordable, portable, and user-friendly autoinjectors, which aligns with the growing demand for patient-centric healthcare solutions.","memo_url":"https://kingscrowd.com/pirouette-medical-on-wefunder-2024/"},{"id":6492,"entity_id":"wefunder:company_investor_profile:6492","name":"Y Combinator","bio":"Startup accelerator and VC firm that's launched over 4,000 companies, including Airbnb, Coinbase, DoorDash, Dropbox, Instacart, Reddit, and Stripe","profile_url":"https://wefunder.com/ycombinator"},{"id":8021,"entity_id":"wefunder:company_investor_profile:8021","name":"Gaingels","bio":"Launched in 2014, Gaingels is a syndicate focused on supporting and investing in startups with diverse leadership, particularly those founded or led by LGBTQ+ individuals. It's a community-driven network that bridges financial support with advocacy.","profile_url":"https://wefunder.com/gaingels.1"},{"id":6494,"entity_id":"wefunder:company_investor_profile:6494","name":"Liquid 2 Ventures","bio":"Liquid 2 is creating a valuable seed-stage ecosystem, defined by a network of deeply rooted connections with advisors, co-investors, and a portfolio of over 750 tech companies.","profile_url":"https://wefunder.com/liquid.2.ventures"},{"id":6495,"entity_id":"wefunder:company_investor_profile:6495","name":"MAGIC Fund","bio":"MAGIC Fund is an early-stage venture capital fund established by founders for founders. They support founders who are addressing daunting challenges globally. To date, they have backed over 200 tech startups worldwide.","profile_url":"https://wefunder.com/magic.fund.1"},{"id":6497,"entity_id":"wefunder:company_investor_profile:6497","name":"Asymmetry Ventures","bio":"Asymmetry Ventures focuses on transformative startups, with a history of early bets on significant emerging companies. They aim to back businesses that not only reach billion-dollar valuations but also impact humanity itself.","profile_url":"https://wefunder.com/asymmetry.ventures"},{"id":7815,"entity_id":"wefunder:company_investor_profile:7815","name":"Joseph Nemmers","bio":"Syndicate Lead","profile_url":"https://wefunder.com/joseph.nemmers.1","endorsement_quote":"I believe in QuicPush as a product, and I have great confidence in the Pirouette leadership team. I am impressed with the intellectual property of the device, and in the technology that has been invested in the manufacturing process. I think QuicPush will offer better product dating and more reliable functionality than the current competitive products, and QuicPush’s unique and ergonomic design will make it much easier for children and adults with limited hand and arm strength to self-inject. The other potential is that QuicPush can become a “Pipeline in a Product,” meaning the device can be used for a wide variety of therapeutic applications."},{"id":8367,"entity_id":"wefunder:company_investor_profile:8367","name":"Clinical Science Partners LLC","bio":"Clinical Science Partners, a healthcare investment firm, specializes in early-stage medical devices and diagnostics. We aim to maximize investment returns through rigorous validation of the clinical science underpinning our investments, focusing exclusive","profile_url":"https://wefunder.com/jeff.blank.1","endorsement_quote":"When we met Conor and his team, we were not only impressed by their design, engineering, and manufacturing capabilities, but also by their commitment to enhancing the patient experience beyond just creating a new \"EpiPen\" for people with severe allergies. Their decision to pursue an intramuscular naloxone product as a better alternative to nasal sprays underscores their commitment to improving lives through innovation. Pirouette is at the forefront of transforming drug delivery, focusing on optimizing patient experience and therefore impacting outcomes. This approach is vital for the adoption and success of essential therapies in areas like obesity (GPL-1), IVF, glucagon, and vaccines, as new medications continue to emerge."},{"id":8368,"entity_id":"wefunder:company_investor_profile:8368","name":"Rivendell Ventures","bio":"Rivendell focuses on pioneering technologies and products at the forefront of computing, physics, and bioscience. Formed by a seasoned group of entrepreneurs, we apply both our financial capital and operational expertise in our investment approach.","profile_url":"https://wefunder.com/rivendell.ventures","endorsement_quote":"As a prior Pirouette investor, Rivendell is excited about this community investment round as a way to directly engage the community of patients and users that Pirouette is tirelessly working to advocate for. We believe that this innovation can save lives and that the Pirouette team will make it happen."}],"relationships":[{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:user:4030866","target_url":"https://wefunder.com/conor.cullinane"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:4023860"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:4023858"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:6559992"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:6559993"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:6559994"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:6559995"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:6559996"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:6559997"},{"source_entity_id":"wefunder:company:141810","relation":"has_team_member","target_entity_id":"wefunder:company_role:4159544"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:3937","target_url":"https://wefunder.com/safar.partners"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:user:4138054","target_url":"https://wefunder.com/kingscrowd.capital"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:7250","target_url":"https://wefunder.com/ycombinator"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:2012","target_url":"https://wefunder.com/gaingels.1"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:user:4150458","target_url":"https://wefunder.com/liquid.2.ventures"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:2435","target_url":"https://wefunder.com/magic.fund.1"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:2248","target_url":"https://wefunder.com/asymmetry.ventures"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11297","target_url":"https://wefunder.com/joseph.nemmers.1"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:user:4232109","target_url":"https://wefunder.com/jeff.blank.1"},{"source_entity_id":"wefunder:company:141810","relation":"has_featured_investor","target_entity_id":"wefunder:notable_investor:11836","target_url":"https://wefunder.com/rivendell.ventures"},{"source_entity_id":"wefunder:company:141810","relation":"has_latest_fundraise","target_entity_id":"wefunder:fundraise:149523"}],"faq":[{"question":"How do investors at this stage get a ROI? What are the trigger events to convert investment money into shares later on?","answer":"Great question! You can learn more about the ROI here: https://help.wefunder.com/#/investor/after-you-invest The triggering event for the SAFE to convert to shares is the next \"Qualified Financing\" as described here: \"In the event that the Company issues and sells Preferred Stock in a bona fide transaction or series of transactions with the principal purpose of raising capital for aggregate proceeds of at least US$10,000,000 at a fixed valuation, including but not limited to, a pre-money or p..."},{"question":"Conor, Few questions. 1. Regarding the narcan, your competition would be not just from other autoinjection products but intranasal products. Even if your autojectable narcan is the best and cheapest on the market how do you compete against intranasal narcan and did any of your...","answer":"Hi David - these are all great questions! “I lost a couple nephews and a niece, and I'm convinced a device like this could have saved them.” -Opioid Dependent User “I absolutely loved the device. The stick function [adhesive base] is great. What you pointed out about nasal sprays, how patient orientation matters, you’ve done a lot of research, I didn’t even think about that and how the drug can dribble down the patient’s face.” -Legislative Assistant (Healthcare) at the U.S. House of Represen..."},{"question":"Are they recyclable maybe even re-usable? Or just one time use and trash? Sorry if you already put that info in the info and I missed it.","answer":"Hi Mical, thanks for the question! At this time the devices are based off of our first generation auto-injector platform and are single-use, disposable systems. The single-use nature aims to make the device intuitive to use and reduce complexity. In the future, we foresee a potential for a next generation version that could be multi-use."},{"question":"Hello Conor, I made an investment, but considering upping it depending upon what I learn from the answers to my questions. - Is there a standard for vial that you are building the platform to? size/format etc. - If yes, what is the friction in introducing new drugs with your p...","answer":"Hi Prakash, thanks for the fantastic questions. The short answer is YES! We use the pharma standards as much as possible to make it simple for partners to pair their drug with our device. The container closure system is a standard type I glass of common ID/OD, and sits in a standard nest/tub configuration for compatibility with the standard fill/finish process. We can operate either way, receiving the drug product and completing all kitting or licensing the device to the partner if they want ..."},{"question":"What is the price of each share of Pirouette Medical Devices on wefunder.com!@","answer":"Hello! The vehicle is a SAFE which converts to equity at the next priced round. Check out https://help.wefunder.com/#/glossary/contract for more information."}],"recent_posts":[],"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-03T23:38:45Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-03T16:03:34Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-03T16:03:34Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2026-02-11T20:26:48Z","as_of":"2026-06-03T23:38:45Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2026-02-11T20:26:48Z","as_of":"2026-06-03T23:38:45Z","confidence":"medium"}}}}}}